

June 2, 2026

The Honorable Michael J. Rodrigues
Chair, Senate Committee on Ways and Means
State House
Boston MA, 02133

Re: Support of S.2632, *An Act relative to the use of artificial intelligence and other software tools in healthcare decision making*

Dear Chairman Rodrigues:

On behalf of MassBio and our over 1,700 members, I write in support of S.2632, *An Act relative to the use of artificial intelligence and other software tools in healthcare decision making*. If passed, this legislation would protect patients from denials, delays, or modifications in health care services by requiring that determinations of medical necessity be made only by licensed health care professionals and physicians.

Too often, patients in Massachusetts are subjected to burdensome and overly administrative utilization reviews that can limit access to life-saving medications and therapies prescribed by medical professionals. As technology advances, carrier and utilization review organizations increasingly rely on artificial intelligence-based software to assist with these processes. While this technology can help mitigate delays and reduce administrative burden, it is imperative that protections are put in place to ensure that patient care is not determined by algorithm-based decisions, but rather by the medical expertise of licensed physicians and health care professionals.

MassBio supports the actions Massachusetts has taken to streamline utilization review practices and reduce barriers that delay care and access to essential health care services and therapies for patients. S.2632 will further support that effort by ensuring that artificial intelligence is not used to make medical determinations that delay health care services by requiring that these decisions are made by health care professionals based on patients' medical history and clinical circumstances.

For these reasons, I respectfully request that S.2632 be advanced from committee with a favorable vote. Thank you for your time and consideration of MassBio's testimony. Should you have further questions or require additional information, please do not hesitate to contact me directly.

Sincerely,



Kendalle Burlin O'Connell
CEO & President
Massachusetts Biotechnology Council (MassBio)